Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
News provided by
Share this article
Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019
(4)
Fourth quarter 2020 EYLEA
® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019
Fourth quarter 2020 Dupixent
(2)
, which are recorded by Sanofi, increased 56% to $1.17 billion versus fourth quarter 2019 and full year 2020 Dupixent global net sales increased 75% versus 2019
Fourth quarter 2020 GAAP diluted EPS was $10.24 and non-GAAP diluted EPS
(1)
™ antibody cocktail for COVID-19 received FDA Emergency Use Authorization; new agreement signed with U.S. government to purchase up to 1.25 million additional doses
Operating income
Fourth quarter operating income was $29 million, up $1 million from the year-ago period. The increase was largely attributable to lower input costs and favorable price mix.
Full-year operating income was $102 million, an increase of $3 million from prior year. The increase was largely attributable to Pakistan pricing actions, strong EMEA specialty sales, and lower operating expenses in Europe. This increase was partially offset by the impacts of stay-at-home orders on Pakistan sales volume in the first half and negative Pakistan foreign currency impacts. Excluding foreign currency impacts, segment operating income was up 7 percent.
Dividends
In December 2020, the Company paid a quarterly dividend of $46 million ($0.64 per share). The Company paid $178 million of dividends in 2020.
(1)
Solid long-term investment performance, with 65% and 72% of assets under management ( AUM ) outperforming relevant benchmarks on a three- and five-year basis, respectively, as at 31 December 2020
AUM increased 12% to US$401.6 billion compared to the prior quarter, reflecting positive markets and improved outflows of US$(1.1) billion
Completed US$27 million of share buybacks during the fourth quarter for a total of US$131 million of share buybacks in 2020
Board declared quarterly dividend of US$0.36 per share
Janus Henderson Group plc (NYSE/ASX: JHG; JHG , the Group ) published its fourth quarter and full-year 2020 results for the period ended 31 December 2020.
Fourth Quarter 2020 Results
Fourth quarter 2020 operating income was US$227.0 million compared to US$156.5 million in the third quarter 2020 and US$154.3 million in the fourth quarter 2019. Adjusted operating income, adjusted for one-time, acquisition and transaction related costs, was US$231.7 million in the
Iteris Reports 5% Revenue Growth Year Over Year with Significant Increases in GAAP Net Income and Adjusted EBITDA for Fiscal Third Quarter – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
KLA Corporation Reports Fiscal 2021 Second Quarter Results
- Total revenues were $1.65 billion, finishing near the high-end of guidance;
- GAAP diluted EPS attributable to KLA was $2.94, and non-GAAP diluted EPS attributable to KLA was $3.24, each also finishing above the mid-point of guidance;
- Cash flow from operations and free cash flow were both records at $561.1 million and $501.9 million, respectively;
- Capital return was $317.1 million with $139.6 million in dividends and $177.5 million in share repurchases
News provided by
Share this article
Share this article
MILPITAS, Calif., Feb. 3, 2021 /PRNewswire/ KLA Corporation (NASDAQ: KLAC) today announced operating results for its second quarter of fiscal year 2021, which ended on Dec. 31, 2020, and reported GAAP net income attributable to KLA of $457 million and GAAP earnings per diluted share attributable to KLA of $2.94 on revenue of $1.65 billion.